Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study.
HbA1c
Hypoglycemia
Semaglutide
Type 2 diabetes
Weight reduction
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
18
10
2023
accepted:
23
11
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
This study aimed to assess the safety and effectiveness of semaglutide, administered either by weekly subcutaneous (SC) injection or orally, in real-life practice in Saudi Arabia in individuals with type 2 diabetes mellitus (T2DM). A retrospective chart review study was conducted at 18 Saudi Arabia centers. An accredited centralized institutional review board approved the study. Medical records were included for individuals of any age ≥ 18 years with uncontrolled T2DM. The primary outcome measure was the laboratory glycated hemoglobin (HbA1c) level. Secondary measures included fasting blood glucose (FBG), weight, and hypoglycemia. All variables were checked after 6 and 12 months of semaglutide initiation. The analysis of this study included 1223 patients with uncontrolled T2DM (HbA1c > 7%). The mean (SD) baseline HbA1c was 10.02% (1.17). HbA1c was reduced by an average of 3.02% (0.84) and 3.17% (0.84) at 6 and 12 months, respectively. Results of a repeated measure analysis of variance (ANOVA) indicated significant differences in HbA1c (p value < 0.001). HbA1c levels at 6 and 12 months were significantly lower, 7.00% (0.70) and 6.85% (0.69), than at baseline, 10.02% (1.17). About 193 patients (56.4%) of the 295 patients having HbA1c < 9% achieved HbA1c of 5.7% or less. The frequency of hypoglycemia events was 4.60 (1.10) in the 3 months before semaglutide was initiated. The frequency of hypoglycemia events in the last 3 months was 2.30 (0.80) events and 0.80 (0.50) events at 6-month and 12-month follow-up visits, respectively. The percent reduction in body mass index (BMI) was an average of 13.07% (1.53) and 19.89% (4.07) at 6 and 12 months, respectively. Lipid profile and blood pressure were improved at 6 and 12 months. Semaglutide, administered either by SC injection or orally, provided substantial glycemic and weight-loss benefits in adults with T2DM.
Identifiants
pubmed: 38110660
doi: 10.1007/s13300-023-01516-z
pii: 10.1007/s13300-023-01516-z
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2023. The Author(s).
Références
International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 8th edition, 2017, http://www.diabetesatlas.org .
Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603–10.
pubmed: 15573186
Alzaid A. Diabetes; the tale of two cultures. Br J Diabetes Vasc Dis. 2012. https://doi.org/10.1177/1474651412444143 .
doi: 10.1177/1474651412444143
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: tesults from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.
doi: 10.1016/j.diabres.2019.107843
pubmed: 31518657
World Health Organization. Diabetes 2022. https://www.who.int/news-room/fact-sheets/detail/diabetes . Accessed 8 Mar 2023.
IDF Diabetes Atlas 2021-10th edition. Saudi Arabia: Diabetes report 2010–2045. https://www.diabetesatlas.org/data/en/country/174/sa.html . Accessed 8 Mar 2023.
IDF Diabetes Atlas 2021–10th edition. Middle East and North Africa fact sheet 2019. https://diabetesatlas.org/upload/resources/material/20191218_144557_mena_factsheet_en.pdf . Accessed 8 Mar 2023.
Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–80.
doi: 10.1021/acs.jmedchem.5b00726
pubmed: 26308095
Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, openlabel, randomized clinical trial. Diabetes Care. 2018;41(2):258–66.
doi: 10.2337/dc17-0417
pubmed: 29246950
Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–54.
doi: 10.1016/S2213-8587(17)30092-X
pubmed: 28385659
Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of onceweekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–66.
doi: 10.1016/S2213-8587(17)30085-2
pubmed: 28344112
Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–9.
doi: 10.1016/j.diabet.2019.101117
pubmed: 31539622
Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as addon to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834–44.
doi: 10.1016/S2213-8587(19)30311-0
pubmed: 31540867
Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–86.
doi: 10.1016/S2213-8587(18)30024-X
pubmed: 29397376
Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–301.
doi: 10.1210/jc.2018-00070
pubmed: 29688502
pmcid: 5991220
Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60.
doi: 10.1016/S2213-8587(17)30013-X
pubmed: 28110911
Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–67.
doi: 10.1016/S2213-8587(19)30066-X
pubmed: 30833170
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
doi: 10.1056/NEJMoa1607141
pubmed: 27633186
Seeger JD, Nunes A, Loughlin AM. Using RWE research to extend clinical trials in diabetes: an example with implications for the future. Diabetes Obes Metab. 2020;22(Suppl 3):35–44.
doi: 10.1111/dom.14021
pubmed: 32250529
pmcid: 7216829
Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26:1033–9.
doi: 10.1002/pds.4297
pubmed: 28913966
pmcid: 5639372
US Department of Health and Human Services (HHS) Office for Civil Rights (OCR). Guidance regarding methods for de-identification of protected health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. HHS.gov. 2012. https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html . Accessed 11 May 2023.
Alsifri S, Almalki A, Sam A, et al. The impact of the FreeStyle Libre™ flash glucose monitoring system on glycemic control in patients with diabetes; observational multicenter 15-months study. Intl J Clin Med. 2022;13:391–404. https://doi.org/10.4236/ijcm.2022.138027 .
doi: 10.4236/ijcm.2022.138027
Di Loreto C, Minarelli V, Nasini G, Norgiolini R, Del Sindaco P. Effectiveness in real world of once weekly semaglutide in people with type 2 diabetes: glucagon-like peptide receptor agonist naïve or switchers from other glucagon-like peptide receptor agonists: results from a retrospective observational study in umbria. Diabetes Ther. 2022;13(3):551–567. https://doi.org/10.1007/s13300-022-01218-y . Erratum in: Diabetes Ther. 2022;13(6):1251.
Holst JJ, Madsbad S. Semaglutide seems to be more effective the other GLP-1Ras. Ann Transl Med. 2017;5:505.
doi: 10.21037/atm.2017.11.10
pubmed: 29299466
pmcid: 5750268
Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473–88.
doi: 10.1172/JCI75276
pubmed: 25202980
pmcid: 4215190
Iorga RA, Bacalbasa N, Carsote M, et al. Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (review). Exp Ther Med. 2020;20:2396–400.
pubmed: 32765722
pmcid: 7401476
Napoli R, Avogaro A, Formoso G, et al. Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian Diabetes Society. Nutr Metab Cardiovasc Dis. 2021;21:S0939–4753(21)00410–5.
Brown RE, Bech PG, Aronson R. Semaglutide once weekly in people with type 2 diabetes: real-world analysis of the Canadian LMC diabetes registry (SPARE study). Diabetes Obes Metab. 2020;22:2013–20.
doi: 10.1111/dom.14117
pubmed: 32538541
pmcid: 7689820
Jain AB, Kanters S, Khurana R, Kissock J, Severin N, Stafford SG. Real-world effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE-DM study. Diabetes Ther. 2021;12(2):527–36. https://doi.org/10.1007/s13300-020-00984-x .
doi: 10.1007/s13300-020-00984-x
pubmed: 33367981
Visaria J, Uzoigwe C, Swift C, Dang-Tan T, Paprocki Y, Willey VJ. Real-world effectiveness of once-weekly semaglutide from a US commercially insured and medicare advantage population. Clin Ther Clin Ther. 2021;43:808–21.
doi: 10.1016/j.clinthera.2021.03.003
pubmed: 33785221
Uzoigwe C, Liang Y, Whitmire S, Paprocki Y. Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a us real-world setting. Diabetes Ther. 2021;12:1475–89.
doi: 10.1007/s13300-021-01053-7
pubmed: 33837922
pmcid: 8099966
Rajamand Ekberg N, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark/Sweden multicentre, prospective, observational study. Prim Care Diabetes. 2021;15:871–8.
doi: 10.1016/j.pcd.2021.06.008
pubmed: 34183269
Rudofsky G, Catarig AM, Favre L, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021;178:108931.
doi: 10.1016/j.diabres.2021.108931
pubmed: 34217773
Hansen KB, Svendstrup M, Lund A, Knop FK, Vilsbøll T, Vestergaard H. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: real-world data from a diabetes out-patient clinic. Diabet Med Diabet Med. 2021;38: e14655.
doi: 10.1111/dme.14655
pubmed: 34291491
Williams DM, Ruslan AM, Khan R, et al. Real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study. Diabetes Ther. 2021;12:801–11.
doi: 10.1007/s13300-021-01015-z
pubmed: 33565043
pmcid: 7872110
Rodbard HW, Dougherty T, Taddei-Allen P. Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. Am J Manag Care. 2020;26(16 Suppl):S335–43.
pubmed: 33439582
Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020;22:1263–77.
doi: 10.1111/dom.14054
pubmed: 32267058
pmcid: 7384149